Biotec Pharmacon and Affymetrix sign new agreement for the SAP enzyme

Tromsø, 25 September, 2011: Biotec Pharmacon ASA, via its subsidiary ArcticZymes
AS, and Affymetrix Inc. have signed a new non-exclusive supply agreement for
deliveries of ArcticZymes' top-selling enzyme Shrimp Alkaline Phosphatase (SAP).
 
Affymetrix has previously held an exclusive right to distribute SAP, whereas the
new agreement enables ArcticZymes to offer SAP for sale also to other
customers.  At the same time the new agreement provides Affymetrix with a secure
long term supply of SAP  at competitive prices and  non-exclusive rights to
market, distribute and sell the product or combinations with other products for
life science and diagnostic applications. The new agreement is effective from
23(rd) September, 2011 and initially runs through December 2017.
 
Sales of the SAP-enzyme are accounting for a majority of sales in ArcticZymes.
 
-Although we have broadened our enzyme portfolio with several new launches over
the past few years, SAP remains our top-selling product. We are currently
building our organization and increasing our sales and marketing capabilities,
and it has been very important for us to gain control over the commercial
development of our SAP enzyme, says Managing Director Jan Buch Andersen in
ArcticZymes.
 
-The new agreement opens the possibility to address potentially large new market
opportunities, at the same time allowing  Affymetrix a secure long term supply
of SAP on competitive terms. Hopefully, this will increase our sales and also
make our revenue and earnings less volatile, says Buch Andersen.
 
For further information:
 
Jan Buch Andersen, Managing Director, ArcticZymes, tel: +47 46746171
 
Svein Lien, CEO Biotec Pharmacon, tel: +47 92289323
 
About Biotec Pharmacon ASA:
Biotec Pharmacon is a biopharmaceutical company that develops and manufactures
new immunomodulatory products and cold adapted marine enzymes. The wholly owned
Biotec BetaGlucans AS focuses on identifying, developing and commercializing
innovative products to meet unmet medical needs in wound treatment, cancer and
gastroenterology. The company's technology is protected by a large patent
portfolio covering amongst others applications of yeast beta glucans as
adjuvants in conjunction with monoclonal antibodies. The subsidiary ArcticZymes
AS (96% owned) aspires to become a leading supplier of novel enzymes for
diagnostics and genetic research.
 
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
 
This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
 
Source: Biotec Pharmacon ASA via Thomson Reuters ONE
 
[HUG#1549504]